Strategic Execution and Study Momentum
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Management attributed the achievement of the 50% enrollment milestone to protocol changes adopted last year and a shift toward a new target clinical site profile.
-
The strategic pivot to nephrologist-led sites has proven effective, with these locations accounting for over 90% of total patient enrollment to date.
-
Operational progress has unlocked an additional $4.1 million financing tranche, reinforcing the company's capital position for the remainder of the study.
-
Management emphasized that nafamostat's 40-year history of use outside the U.S. is a key driver in attracting high-quality clinical institutions to the NEPHRO study.
-
The company is maximizing its FDA-granted capacity by adding final sites to reach the 14-site limit, primarily to build clinical awareness ahead of potential commercialization.
-
Performance drivers include the simplicity of the study's titration schedule, which management noted has been well-received by clinical staff compared to existing anticoagulants.
Clinical Timelines and Financial Outlook
-
Talphera expects to complete NEPHRO study enrollment within 2026, with top-line data anticipated approximately one month after the last patient is out.
-
The company plans to file a Premarket Approval (PMA) application following data readout, targeting potential FDA approval of Niyad in 2027.
-
Financial guidance indicates that current cash plus approximately $16 million in remaining conditional tranches should fund operations through the potential PMA approval.
-
The two remaining financing tranches are expected to close concurrently with the announcement of top-line data and study completion later this year.
-
Management's outlook for the second half of 2026 assumes continued steady patient flow, though they acknowledged enrollment can fluctuate in 'ebbs and flows'.
Operational and Financial Context
-
Cash operating expenses increased to $3.9 million in Q1 2026, up from $2.9 million year-over-year, primarily driven by higher Niyad development and enrollment costs.
-
The company is utilizing a blinded study design where both placebo and active treatment are administered identically to maintain protocol integrity and ease of use.
-
Management highlighted a competitive advantage in nafamostat's metabolism, which is not dependent on specific organ function, unlike heparin or citrate.
Q&A Session Insights
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Future enrollment milestones and data communication timing
-
Management will not provide a 75% enrollment update as remaining financing tranches are tied only to full study completion.
-
Top-line data is expected within one month of the 'last patient out' due to the short 24-hour primary and 72-hour secondary endpoints.
Clinical site feedback and titration stability
-
Clinical staff reported high satisfaction with the ease of administration and the lack of variability in test results once a stable dose is reached.
-
Approximately 70% of cases reach the target range at the first starting dose, with nearly all patients stabilized by the end of the first hour.
Current standard of care and competitive landscape at study sites
-
The majority of participating sites do not have a first-line anticoagulant for CRRT, instead using heparin or citrate only as 'rescue' therapies.
-
Only one site currently uses heparin as a standard of care, and no sites use citrate as their primary intervention, highlighting a significant unmet need for a first-line option.
